Search Results

1 - 10 of 53 items :

  • "malignant lymphoma" x
Clear All

treatment of anemia associated with hematological malignancy. Hematological Oncology. 2001;19(1):19-30. 15. Truong Pauline T, Parhar Tarnjit BS, Hart J, Alexander Cheryl, Wai Elaine S. Population-Based Analysis of the Frequency of Anemia and its Management Before and During Chemotherapy in Patients With Malignant Lymphoma. American Journal of Clinical Oncology. 2010;33(5):465-468. 16. Pirker R. Safety considerations for erythropoietin treatment in patients with cancer, Expert Opinion on Drug Safety. 2007;6(1):63-69. 17. Deger M, Eisterer W, Kutikova Lucie, Salek S


Introduction: Autologous hematopoietic stem cell transplantation (ASCT) represents a standard therapy in the management of hematologic malignancies such as malignant lymphomas and has used for approximately three decades. The aim of this study was to determine the occurring post-ASCT complications and their impact on the patients’ recovery for a better management.

Material and methods: An observational retrospective study was performed during a five-year period between 2012 and 2017, involving 58 classical Hodgkin lymphoma and 36 non-Hodgkin lymphoma patients, who underwent ASCT in the Bone Marrow Transplantation Unit of Tîrgu Mureş. The main analyzed complications were: infections, bleeding, hydroelectrolytic disorders, and hypoalbuminemia.

Results: After data analysis we found that 17 patients (18%) presented microbiologically confirmed infection, 10 patients (11%) presented clinically non-significant bleeding, 39 patients (42%) presented electrolyte disorders, and 33 patients (36%) presented hypoalbuminemia, obtaining a positive correlation between the rate of adverse events after ASCT with age (r = 0.9914, p = 0.0009) and the average hospitalization period (r = 1, p <0.00001).

Conclusions: The identification of adverse events and their correlation with the patients’ clinical outcome can lead to better patient management and a faster recovery after ASCT.

reduced folate carrier ( RFC ), located in a 40719 bp region at chromosome 21q22.3, is coding for solute folate carrier ( RFC1 ), a major transporter of folates and antifolates into the cell. The antifolate methotrexate (MTX) is a cytotoxic drug which is used in current treatment regimens for childhood acute lymphoblastic leukaemia (ALL) 2 , and non-Hodgkin malignant lymphoma (NHML). 3 , 4 The most frequently studied SLC19A1 polymorphism is rs1051266 in the second exon of the SLC19A1 , which results in amino acid substitution of arginine for histidine (H27R) 5 in


Introduction: Oral mucositis characterized by inflammation of the oral mucosa, ulcers, angular cheilitis, accompanied by pain in the maxillary facial area are symptoms of patients who have undergone cytostatic treatment, affecting over 75% of high-risk patients.

Material and methods: From the total of 182 patients with hematological malignancies, we selected 59 patients, diagnosed with malignant lymphomas and treated at the Hematology Department of the Medical Clinic 1 in Tîrgu Mureș, between July 2013 and June 2016, analyzing the data in the data observation sheets. The study is a retrospective one.

Results: In the group of patients studied, who were treated based on the aforementioned cytostatic plans, we found that the CVP + Rituximab plan frequently causes 1st and 2nd class stomatitis, with no patients with 3rd and 4th class stomatitis. The CHOP + Rituximab therapy plan in a total of 80 applications had complications of 1st and 2nd class stomatitis, much more frequent 1st class without stomatitis of 2nd and 4th degree. Grade III stomatitis occurs in two cases in the CHOP-Bleo belts. Introducing dental medicine in the context of medical multidisciplinarity in oncology hematology is a real necessity because the oral complications of chemotherapy treatments by their severity can lead to compromise of the treatment protocol by reducing the doses or even stopping the treatment

Conclusions: Malignant hemopathies represent a significant percentage in dental disorders, and among them, the maximum severity belongs to the non-Hodgkin and Hodgkin malignant lymphomas. Stomatitis, also called gingivotoxic stomatitis caused by medication, is an acute oral complication, with erythema and edema of the entire oral cavity. The role of the dentist in the diagnosis, prevention and treatment of oral lesions, following the cytostatic therapy, is extremely important.

metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma. Eur J Clin Pharmacol 2011; 67: 993-1006. 4. Erculj N, Kotnik BF, Debeljak M, Jazbec J, Dolzan V. Influence of folate pathway polymorphisms on high-dose methotrexate-related toxicity and survival in childhood acute lymphoblastic leukemia. Leuk Lymphoma 2012; 53: 1096-104. 5. Jazbec J, Kitanovski L, Aplenc R, Debeljak M, Dolzan V. No evidence of association of methylenetetrahydrofolate reductase polymorphism with occurrence of second neoplasms

References 1. Sarris A.H., Papadimitrakopoulou V., Dimopoulos M.A., Smith T., Pugh W., Ha C.S., McLaughlin P., Callender D., Cox J., Cabanillas F. - Primary parotid lymphoma: the effect of International Prognostic Index on outcome. Leuk Lymphoma., 1997;26(1-2):49-56. 2. Gleeson M.J., Bennett M.H., Cawson R.A. - Lymphomas of salivary glands. Cancer, 1986;58(3):699-704. 3. Harris N.L. - Lymphoid proliferations of the salivary glands. Am J Clin Pathol., 1999;111(1 Suppl 1):S94-S103. 4. Ampil F.L., Misra R.P. - Malignant lymphoma of the salivary gland: Case reports

Haematol. 1994;88(2):392-394. 5. Pozzato G, Mazzaro C, Crovatto M, Modolo ML, Ceselli S, Mazzi G, et al. Low-grade malignant lymphoma, hepatitis C virus infection, and mixed cryoglobulinemia. Blood. 1994 Nov 1;84(9):3047-53. 6. Mele A, Pulsoni A, Bianco E, Musto P, Szklo A, Sanpaolo MG et al. Hepatitis C virus and B-cell non- Hodgkin lymphomas: an italian multicenter case- control study. Blood. 2003;102(3):996-999. 7. Duberg A-S, Nordstrom M, Torner A, Reichard O, Strauss R, Janson R et al. Non-Hodgkin’s lymphoma and other neoplastic malignancies in Swedish patients with


Non-Hodgkin malignant lymphomas represent a heterogeneous group of monoclonal tumors developing from cells belonging to the immune system. Primary gastric lymphomas are defined as those malignant limphoproliferative diseases whose initial symptoms are located in the stomach or tumor mass located in the stomach. This paper aims to present a new case of primary gastric non Hodgkin lymphoma diagnosed by histologic and immunohistochemical examination of a partial gastrectomy specimen. The patient is a 51-years old man with a history of smoking, hospitalized for asthenia, hematemesis and melena. Microscopically the tumor consisted of mature small lymphocytes admixed with plasmocitoid lymphocytes and mature plasmocytes. Some of the tumoral cells showed citoplasmatic pas positive inclusions. Immunohistochemical stains were strongly positive for CD20 and 30-40% positive for Ki67.Based on the clinical and histological findings, a diagnosis of gastric primary non-Hodgkin lymphoma was established.


Background: Primary central nervous system lymphoma (PCNSL) involving the hypothalamus and pituitary gland is extremely rare. Therefore, no case to our knowledge has been reported to date.

Objective: We described our findings in a 48-year-old immunocompetent man, who presented with four months progressive diabetes insipidus (DI) and two months subsequent headache.

Methods and Results: A radiological study and magnetic resonance imaging (MRI) suggested a homogeneous enhancing dumbbell-shaped lesion, 2.4⃞1.2 cm in size, involving both the hypothalamus and pituitary gland. A brain biopsy was conducted through a transnasal transsphenoidal approach, and a final histopathological diagnosis of the tumor was confirmed as diffuse large B-cell malignant lymphoma. After extensive tumor surveys, including computed tomography, MRI, ultrasound, bone marrow biopsy, lumbar puncture, and positron emission tomography (PET), no evidence of other lesions found. Subsequently, he received six cycles of intravenous highdose methotrexate-based chemotherapy followed by one cycle of whole-brain radiotherapy. The progressive DI and headache completely resolved and he was in good health 11 months later.

Conclusion: Clinicians should consider the possibility of PCNSL in non specific clinical presentations.

Background. Positron emission tomography (PET) with F-18-labeled fluorodeoxyglucose (FDG) provides remarkable accuracy in detection, treatment monitoring and follow-up of systemic malignant lymphoma. Its value in the management of patients with primary central nervous system lymphoma (PCNSL) is less clear.

Patients and methods. In a prospective trial, 42 FDG-PET examinations were performed in ten immunocompetent patients with newly diagnosed or recurrent PCNSL before and repeatedly during and after the treatment. Brain and whole body FDG-PET were compared to brain MRI and extra-cerebral CT, respectively.

Results. Before the treatment, 6 of 10 patients had congruent findings on FDG-PET and MRI of the brain. Three patients had lesions on brain MRI, not detected by FDG-PET. One patient had additional FDG-PET positive lesions inconspicuous in MRI. The follow-up suggested FDG-PET to be false positive in these lesions. After the treatment, brain PET was in agreement with MRI in 6 of 8 patients. In the remaining 2 patients there were persistent lesions in brain MRI whereas FDG-uptake was reduced to normal values. In the long-term follow-up of 5 patients (63-169 weeks), 3 patients retained normal in both PET and MRI. In 2 patients a new focal pathologic FDG-uptake was detected 69 and 52 weeks after the end of the treatment. In one of these patients, recurrence was confirmed by MRI not until 9 weeks after PET.

Conclusions. Brain FDG-PET may contribute valuable information for the management of PCNSL, particularly in the assessment of the treatment response. Integration of FDG-PET into prospective interventional trials is warranted to investigate prognostic and therapeutic implications.